Heart bailout by cell therapy

Introducing an acceptable test for comparing cell accountability

Research output: Contribution to journalArticle

Abstract

Cell therapy for cardiovascular disease is still in its initial phase of development and hence stringent studies are now required for comparison between available approaches using validated experimental models. The best cell for regenerative purposes should have the ability to stimulate vascular repair and cardiomyogenesis in a time-programmable fashion, cooperating with reparative processes afforded by resident cells. However, these requirements are often unreachable with individual cell types currently used in clinical trials as documented by an interesting article from Barclay and colleagues in the current issue of Stem Cell Research and Therapy.

Original languageEnglish
Article number32
JournalStem Cell Research and Therapy
Volume3
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Social Responsibility
Cell- and Tissue-Based Therapy
Stem cells
Repair
Stem Cell Research
Aptitude
Blood Vessels
Theoretical Models
Cardiovascular Diseases
Clinical Trials

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Molecular Medicine
  • Cell Biology
  • Medicine (miscellaneous)
  • Medicine(all)

Cite this

@article{6d682b0e1b0741c9b10fa261c52b5b3a,
title = "Heart bailout by cell therapy: Introducing an acceptable test for comparing cell accountability",
abstract = "Cell therapy for cardiovascular disease is still in its initial phase of development and hence stringent studies are now required for comparison between available approaches using validated experimental models. The best cell for regenerative purposes should have the ability to stimulate vascular repair and cardiomyogenesis in a time-programmable fashion, cooperating with reparative processes afforded by resident cells. However, these requirements are often unreachable with individual cell types currently used in clinical trials as documented by an interesting article from Barclay and colleagues in the current issue of Stem Cell Research and Therapy.",
author = "Paolo Madeddu",
year = "2012",
doi = "10.1186/scrt123",
language = "English",
volume = "3",
journal = "Stem Cell Research and Therapy",
issn = "1757-6512",
publisher = "BioMed Central Ltd.",
number = "4",

}

TY - JOUR

T1 - Heart bailout by cell therapy

T2 - Introducing an acceptable test for comparing cell accountability

AU - Madeddu, Paolo

PY - 2012

Y1 - 2012

N2 - Cell therapy for cardiovascular disease is still in its initial phase of development and hence stringent studies are now required for comparison between available approaches using validated experimental models. The best cell for regenerative purposes should have the ability to stimulate vascular repair and cardiomyogenesis in a time-programmable fashion, cooperating with reparative processes afforded by resident cells. However, these requirements are often unreachable with individual cell types currently used in clinical trials as documented by an interesting article from Barclay and colleagues in the current issue of Stem Cell Research and Therapy.

AB - Cell therapy for cardiovascular disease is still in its initial phase of development and hence stringent studies are now required for comparison between available approaches using validated experimental models. The best cell for regenerative purposes should have the ability to stimulate vascular repair and cardiomyogenesis in a time-programmable fashion, cooperating with reparative processes afforded by resident cells. However, these requirements are often unreachable with individual cell types currently used in clinical trials as documented by an interesting article from Barclay and colleagues in the current issue of Stem Cell Research and Therapy.

UR - http://www.scopus.com/inward/record.url?scp=84865265975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865265975&partnerID=8YFLogxK

U2 - 10.1186/scrt123

DO - 10.1186/scrt123

M3 - Article

VL - 3

JO - Stem Cell Research and Therapy

JF - Stem Cell Research and Therapy

SN - 1757-6512

IS - 4

M1 - 32

ER -